Alector (ALEC) Stock Analysis
NASDAQHealthcareBiotechnology
What Alector does
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Key metrics
ETFs linked to ALEC
Broad-market and Healthcare sector ETFs an investor holding Alector is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how ALEC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze ALEC in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Alector?
- Alector trades under the ticker ALEC on NASDAQ.
- Which exchange is ALEC listed on?
- ALEC is listed on NASDAQ.
- What sector does Alector operate in?
- Alector is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze ALEC in a portfolio?
- PortView shows ALEC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.